RNAC Q1 2020 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$19M

Net Income

-$20M

EPS (Diluted)

$-6.21

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$89M

Total Liabilities

$98M

Stockholders' Equity

-$9M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$10,000	-100.0%
Gross Profit	$0	$10,000	-100.0%
Operating Income	-$19M	-$12M	-58.8%
Net Income	-$20M	-$12M	-62.5%